Dyne Therapeutics Inc (DYN) Stock Price, Quote & News

Company Profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifyi...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 786 8230

Fax: 781 786 8866

Website: www.dyne-tx.com

Address:

1560 Trapelo Road, Waltham, United States

parcha Sep. 14 at 1:18 PM

$DYN https://share.google/tLxsHNEkU4chJpbxs Today and tomorrow conferences

0 · Reply

Baazigar123 Sep. 11 at 2:37 PM

$DYN more drop ahead

0 · Reply

blueharvest77 Sep. 11 at 1:17 PM

$DYN This can be green?!

0 · Reply

SmartInvesting2024 Sep. 11 at 11:07 AM

$DYN oversold

0 · Reply

PensionPulse Sep. 10 at 2:56 PM

$BCRX $BHVN $DYN $SRPT Not a good week for biotechs and with end of quarter ahead, might get worse for losers

0 · Reply

BioRich Sep. 9 at 6:05 PM

$DYN Nice wounded duck opportunity here. Macro market hurting most, and $DYN is no exception. Will continue to watch for updates, but I still believe this was a massive sympathy oversell. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money.

0 · Reply

anachartanalyst Sep. 9 at 4:02 PM

$DYN https://anachart.com/wp-content/uploads/2026/09/1788969696_soc-img.jpg

0 · Reply

StocktwitsNews Sep. 9 at 3:41 PM

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes $DYN $NVS https://stocktwits.com/news/equity/markets/dyn-stock-extends-selloff-what-is-wall-street-saying/cZt7eq1RJz8

0 · Reply

Market_Pulse_Report Sep. 9 at 11:54 AM

$DYN

0 · Reply

CC_Abbott Sep. 9 at 11:22 AM

$DYN drop on NVS' DM1 trial news is a [long] opportunity. If interested, a mention in BioSpace coverage of NVS' news: https://www.biospace.com/drug-development/novartis-12b-avidity-acquisition-hits-phase-3-speedbump-as-dystrophy-drug-disappoints?utm_campaign= DYN also have Jan 21 2027 PDUFA for their accelerated approval BLA in exon 51 DMD Disclosure: Long DYN; NFA

0 · Reply

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 15, 2026, 10:50 AM EDT - 5 days ago

Dyne Therapeutics Transcript: 2026 Global Healthcare Conference

Sep 14, 2026, 9:15 AM EDT - 6 days ago

Dyne Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Sep 11, 2026, 10:20 AM EDT - 9 days ago

Dyne Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

2026-09-09T12:36:30.000Z - 11 days ago

Dyne Therapeutics price target lowered to $36 from $45 at Morgan Stanley

NVS

2026-09-09T12:25:23.000Z - 11 days ago

Dyne Therapeutics price target lowered to $30 from $35 at RBC Capital

2026-09-09T11:00:59.000Z - 11 days ago

Dyne Therapeutics price target lowered to $26 from $30 at Baird

2026-09-08T20:35:32.000Z - 11 days ago

Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan

NVS

Sep 8, 2026, 1:02 PM EDT - 11 days ago

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

SRPT NVS

2026-09-08T16:05:49.000Z - 11 days ago

Dyne Therapeutics falls -15.4%

2026-09-08T14:06:21.000Z - 12 days ago

Dyne Therapeutics falls -22.3%

2026-09-08T12:00:30.000Z - 12 days ago

Dyne Therapeutics should be bought on weakness, says Stifel

NVS

Sep 8, 2026, 7:51 AM EDT - 12 days ago

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

2026-09-08T11:45:28.000Z - 12 days ago

Dyne ‘claims frontrunner status in DM1’ after Novartis failure, says Jefferies

NVS

2026-09-08T11:40:20.000Z - 12 days ago

Dyne Therapeutics sinks after Novartis myotonic dystrophy miss

NVS

Sep 3, 2026, 7:30 AM EDT - 17 days ago

Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

Sep 2, 2026, 7:30 AM EDT - 18 days ago

Dyne Therapeutics to Participate in Upcoming Investor Conferences

2026-07-31T14:45:26.000Z - 7 weeks ago

Dyne Therapeutics price target lowered to $45 from $47 at Morgan Stanley

2026-07-29T21:00:34.000Z - 7 weeks ago

Dyne Therapeutics reports Q2 EPS ($1.08), consensus (75c)

Jul 29, 2026, 4:30 PM EDT - 7 weeks ago

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Jul 29, 2026, 7:00 AM EDT - 7 weeks ago

Dyne Therapeutics Quarterly report: Q2 2026

Jul 29, 2026, 7:00 AM EDT - 7 weeks ago

Dyne Therapeutics Earnings release: Q2 2026

2026-07-28T11:40:13.000Z - 7 weeks ago

Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial

Jul 28, 2026, 7:30 AM EDT - 7 weeks ago

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

Jul 23, 2026, 4:05 PM EDT - 1 month ago

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

2026-07-23T11:20:36.000Z - 1 month ago

Dyne Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-07-23T10:25:16.000Z - 1 month ago

Dyne Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-07-22T04:05:08.000Z - 2 months ago

Dyne Therapeutics 18.3M share Spot Secondary priced at $20.50

Jul 21, 2026, 10:46 PM EDT - 2 months ago

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

Jul 21, 2026, 4:46 PM EDT - 2 months ago

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Jul 20, 2026, 7:30 AM EDT - 2 months ago

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Jun 22, 2026, 4:10 PM EDT - 2 months ago

Dyne Therapeutics Appoints Barry Greene to Board of Directors

Jun 17, 2026, 7:30 AM EDT - 3 months ago

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

HTGC

Jun 3, 2026, 9:55 AM EDT - 3 months ago

Dyne Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 7:30 AM EDT - 3 months ago

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

May 26, 2026, 7:30 AM EDT - 3 months ago

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

May 20, 2026, 11:00 AM EDT - 4 months ago

Dyne Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 7:46 AM EDT - 4 months ago

Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval

May 13, 2026, 7:00 AM EDT - 4 months ago

Dyne Therapeutics Slides: AGM presentation

May 11, 2026, 7:30 AM EDT - 4 months ago

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 11, 2026, 7:00 AM EDT - 4 months ago

Dyne Therapeutics Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 4 months ago

Dyne Therapeutics Earnings release: Q1 2026

Apr 27, 2026, 4:34 PM EDT - 4 months ago

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Apr 23, 2026, 8:00 AM EDT - 5 months ago

Dyne Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 5 months ago

Dyne Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 5 months ago

Dyne Therapeutics Proxy statement: Proxy filing

Apr 1, 2026, 7:30 AM EDT - 5 months ago

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Mar 17, 2026, 4:00 PM EDT - 6 months ago

Dyne Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 8, 2026, 6:01 PM EDT - 6 months ago

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

Mar 8, 2026, 6:00 PM EDT - 6 months ago

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

Mar 4, 2026, 11:50 AM EST - 6 months ago

Dyne Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:30 AM EST - 6 months ago

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 2, 2026, 7:00 AM EST - 6 months ago

Dyne Therapeutics Earnings release: Q4 2025

Mar 2, 2026, 7:00 AM EST - 6 months ago

Dyne Therapeutics Annual report: Q4 2025

Mar 2, 2026, 7:00 AM EST - 6 months ago

Dyne Therapeutics Annual report: Q4 2025

Mar 2, 2026, 6:00 AM EST - 6 months ago

Dyne Therapeutics Slides: Corporate presentation

Feb 22, 2026, 4:00 PM EST - 6 months ago

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

Feb 2, 2026, 8:30 AM EST - 7 months ago

Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

Jan 20, 2026, 7:30 AM EST - 8 months ago

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

Jan 14, 2026, 8:15 PM EST - 8 months ago

Dyne Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 8 months ago

Dyne Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:30 AM EST - 8 months ago

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 7:30 AM EST - 9 months ago

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

Dec 9, 2025, 9:42 PM EST - 9 months ago

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

Dec 8, 2025, 8:00 AM EST - 9 months ago

Dyne Therapeutics Transcript: Study Result

Dec 8, 2025, 8:00 AM EST - 9 months ago

Dyne Therapeutics Press release: Study Result

Dec 8, 2025, 8:00 AM EST - 9 months ago

Dyne Therapeutics Slides: Study Result

Dec 8, 2025, 6:30 AM EST - 9 months ago

Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

Dec 7, 2025, 11:00 AM EST - 9 months ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

Dec 2, 2025, 9:35 AM EST - 9 months ago

Dyne Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 17, 2025, 10:00 AM EST - 10 months ago

Dyne Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 9:20 AM EST - 10 months ago

Dyne Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 10:00 AM EST - 10 months ago

Dyne Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 4:10 PM EST - 10 months ago

Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 5, 2025, 7:00 AM EST - 10 months ago

Dyne Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Dyne Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 7:30 AM EST - 10 months ago

Dyne Therapeutics to Present at Upcoming Investor Conferences

Oct 27, 2025, 4:54 PM EDT - 10 months ago

This biotech's stock soared as investors look for the next buyout target

Oct 6, 2025, 6:01 PM EDT - 11 months ago

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Oct 2, 2025, 4:05 PM EDT - 11 months ago

Dyne Therapeutics Appoints Brian Posner to its Board of Directors

Sep 29, 2025, 8:35 AM EDT - 11 months ago

Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy

Sep 8, 2025, 9:15 AM EDT - 1 year ago

Dyne Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 5, 2025, 9:45 AM EDT - 1 year ago

Dyne Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 4, 2025, 7:30 AM EDT - 1 year ago

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)

Jul 28, 2025, 4:10 PM EDT - 1 year ago

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 28, 2025, 7:00 AM EDT - 1 year ago

Dyne Therapeutics Earnings release: Q2 2025

Jul 28, 2025, 7:00 AM EDT - 1 year ago

Dyne Therapeutics Quarterly report: Q2 2025

Jul 16, 2025, 7:00 AM EDT - 1 year ago

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

Jul 2, 2025, 4:01 PM EDT - 1 year ago

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jun 30, 2025, 9:45 PM EDT - 1 year ago

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

Jun 30, 2025, 4:01 PM EDT - 1 year ago

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

Jun 24, 2025, 3:43 AM EDT - 1 year ago

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN

Jun 17, 2025, 1:35 PM EDT - 1 year ago

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Dyne Therapeutics Transcript: Status Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Dyne Therapeutics Press release: Status Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Dyne Therapeutics Slides: Status Update

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Jun 16, 2025, 9:12 PM EDT - 1 year ago

Dyne Therapeutics Slides: Investor Presentation

Jun 16, 2025, 4:05 PM EDT - 1 year ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

parcha Sep. 14 at 1:18 PM

$DYN https://share.google/tLxsHNEkU4chJpbxs Today and tomorrow conferences

0 · Reply

Baazigar123 Sep. 11 at 2:37 PM

$DYN more drop ahead

0 · Reply

blueharvest77 Sep. 11 at 1:17 PM

$DYN This can be green?!

0 · Reply

SmartInvesting2024 Sep. 11 at 11:07 AM

$DYN oversold

0 · Reply

PensionPulse Sep. 10 at 2:56 PM

$BCRX $BHVN $DYN $SRPT Not a good week for biotechs and with end of quarter ahead, might get worse for losers

0 · Reply

BioRich Sep. 9 at 6:05 PM

0 · Reply

anachartanalyst Sep. 9 at 4:02 PM

$DYN https://anachart.com/wp-content/uploads/2026/09/1788969696_soc-img.jpg

0 · Reply

StocktwitsNews Sep. 9 at 3:41 PM

0 · Reply

Market_Pulse_Report Sep. 9 at 11:54 AM

$DYN

0 · Reply

CC_Abbott Sep. 9 at 11:22 AM

0 · Reply

notreload_ai Sep. 9 at 10:20 AM

$NVS DM1 trial miss hit $DYN. JPMorgan cut DYN to Underweight with a $10 target; Stifel and Jefferies stay Buy. https://notreload.xyz/xy/jpmorgan-cuts-dyne-after-novartis-trial-fail/

0 · Reply

Mmiddleb Sep. 9 at 9:42 AM

$DYN Jefferies reiterated Buy/$50 yesterday, Stifel maintained Buy/$37, LifeSci moved to roughly $40, and this morning Raymond James trimmed its target only modestly, $40 → $37 while retaining Strong Buy specifically because of the increased DM1 risk. The broader analyst consensus remains around $39–$43, depending on the data source.

0 · Reply

TNNStockAnalysisNews Sep. 9 at 2:35 AM

Top Losing Stocks Today, Sep 8, 2026: $DYN Down 22% $NVS Down 12% $SGML Down 11% $SRPT Closed $20.18, Down 10.3% $AMGN Down ~9% https://truthsandnews.com/markets/top-losing-stocks-today-sep-8-2026-biotech-sinks

0 · Reply

Market_Pulse_Report Sep. 9 at 1:20 AM

$DYN I just went over all of the FINANCIALS!!! I did my homework, sharing this video with you guys! https://youtu.be/No77OMn6NwA

0 · Reply

potrero Sep. 8 at 8:37 PM

$PEPG $DYN

0 · Reply

StocktwitsNews Sep. 8 at 8:09 PM

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy $NVS $DYN $SRPT https://stocktwits.com/news/equity/markets/nvs-stock-on-track-for-worst-day-in-over-20-years-after-second-trial-failure-in-a-week-dyn-srpt-slip-in-sympathy/cZtEeAyRJy2

0 · Reply

OptionRunners Sep. 8 at 5:02 PM

$DYN another 5,000 of these March 2027 spreads. See if they all carry over to the OI tomorrow. Would be 20k total now.

0 · Reply

OptionRunners Sep. 8 at 4:21 PM

$DYN another 5,000 in these spreads. 15k total now

0 · Reply

OptionRunners Sep. 8 at 4:06 PM

$DYN dip buyer coming in with this $2.5M call spread ahead of several conferences over the next week. Stock down on the $NVS failure

0 · Reply

XQuise Sep. 8 at 3:59 PM

$DYN 👍🏻📉📈🤑😁

0 · Reply

Mmiddleb Sep. 8 at 3:07 PM

$DYN

0 · Reply

YouVSYou Sep. 8 at 2:34 PM

$DYN $NVS $SRPT Solid bounce DYN

0 · Reply

Market Cap	3.20B
Revenue (ttm)	0.00
Net Income (ttm)	-446.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.30

Volume	4,849,500
Avg Vol	2,708,788
Day's Range	N/A - N/A
Shares Out	186.75M
Stochastic %K	4%
Beta	1.08
Analysts	Strong Sell
Price Target	$37.20